Search Result

Results for "

opioid antagonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Opioid Receptor (156) 5-HT Receptor (6) Adenylate Cyclase (1) Adrenergic Receptor (5) Amino Acid Derivatives (1) Angiotensin-converting Enzyme (ACE) (1) Apoptosis (3) Bacterial (2) Beta-secretase (1) Cannabinoid Receptor (1) Cytochrome P450 (1) Dopamine Receptor (11) Drug Intermediate (1) Drug Isomer (1) Drug Metabolite (3) Endogenous Metabolite (2) ERK (5) Flavivirus (1) Fluorescent Dye (2) Fungal (2) GABA Receptor (9) GlyT (3) Histamine Receptor (5) iGluR (7) Isotope-Labeled Compounds (15) mAChR (2) Neurokinin Receptor (2) Neuropeptide FF Receptor (2) NF-κB (5) NO Synthase (5) Orexin Receptor (OX Receptor) (1) P2X Receptor (3) p38 MAPK (10) Potassium Channel (7) Protein Arginine Deiminase (1) PTHR (1) Reactive Oxygen Species (ROS) (3) Reference Standards (19) Sigma Receptor (4) Sodium Channel (1) STAT (2) Toll-like Receptor (TLR) (5) TRP Channel (3) Urotensin Receptor (1)
By Research Areas:	Cancer (17) Cardiovascular Disease (8) Endocrinology (4) Infection (4) Inflammation/Immunology (20) Metabolic Disease (15) Neurological Disease (167)

By Targets:

Opioid Receptor (156)

5-HT Receptor (6)

Adenylate Cyclase (1)

Adrenergic Receptor (5)

Amino Acid Derivatives (1)

Angiotensin-converting Enzyme (ACE) (1)

Apoptosis (3)

Bacterial (2)

Beta-secretase (1)

Cannabinoid Receptor (1)

Cytochrome P450 (1)

Dopamine Receptor (11)

Drug Intermediate (1)

Drug Isomer (1)

Drug Metabolite (3)

Endogenous Metabolite (2)

ERK (5)

Flavivirus (1)

Fluorescent Dye (2)

Fungal (2)

GABA Receptor (9)

GlyT (3)

Histamine Receptor (5)

iGluR (7)

Isotope-Labeled Compounds (15)

mAChR (2)

Neurokinin Receptor (2)

Neuropeptide FF Receptor (2)

NF-κB (5)

NO Synthase (5)

Orexin Receptor (OX Receptor) (1)

P2X Receptor (3)

p38 MAPK (10)

Potassium Channel (7)

Protein Arginine Deiminase (1)

PTHR (1)

Reactive Oxygen Species (ROS) (3)

Reference Standards (19)

Sigma Receptor (4)

Sodium Channel (1)

STAT (2)

Toll-like Receptor (TLR) (5)

TRP Channel (3)

Urotensin Receptor (1)

By Research Areas:

Cancer (17)

Cardiovascular Disease (8)

Endocrinology (4)

Infection (4)

Inflammation/Immunology (20)

Metabolic Disease (15)

Neurological Disease (167)

194

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Opioid Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17417

Naloxone hydrochloride 5+ Cited Publications	Opioid Receptor	Neurological Disease Cancer
Naloxone hydrochloride is an antagonist of Opioid receptor. Naloxone hydrochloride alleviates opioid-overdose-induced respiratory depression. Naloxone hydrochloride may cause pulmonary edema and cardiac arrhythmias .

HY-101718

Aticaprant 5+ Cited Publications CERC-501; LY-2456302	Opioid Receptor	Neurological Disease
Aticaprant (CERC-501) is a potent and centrally-penetrant kappa opioid receptor antagonist with a K_i of 0.807 nM.

HY-17417A

Naloxone 5+ Cited Publications	Opioid Receptor	Neurological Disease Cancer
Naloxone is an antagonist of Opioid receptor. Naloxone alleviates opioid-overdose-induced respiratory depression. Naloxone may cause pulmonary edema and cardiac arrhythmias .

HY-19627A

Naldemedine tosylate 1 Publications Verification S-297995 tosylate	Opioid Receptor	Neurological Disease Metabolic Disease
Naldemedine (S-297995) tosylate is an orally active *μ-opioid* receptor** antagonist (PAMORA) . Naldemedine tosylate shows potent binding affinities (K_i=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC₅₀=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors . Naldemedine can be used in opioid-induced constipation (OIC) research . Naldemedine tosylate is predicted to bind to 3CL ^pro encoded by SARS-CoV2 genome .

HY-76711

Naltrexone	Opioid Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Naltrexone is an orally active, long-acting opioid receptor (opioid receptor) antagonist. Naltrexone blocks the euphoric effects of exogenous opioids and reduces alcohol craving by blocking opioid receptors (μ, κ, and δ) as well as opioid growth factor receptors. Low doses of Naltrexone are used to relieve chronic pain, treat inflammatory diseases and inhibit tumor growth, while high doses or continuous administration exert pro-inflammatory or pro-proliferative effects. Naltrexone relieves intractable pruritus caused by psoriasis, atopic dermatitis and other conditions, and its combination with Bupropion (HY-B0403) inhibits food craving, thereby reducing body weight .

HY-107744

Nalmefene 1 Publications Verification	Opioid Receptor Apoptosis Reactive Oxygen Species (ROS) NO Synthase Toll-like Receptor (TLR) p38 MAPK NF-κB	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Nalmefene is a BBB-penetrable opioid receptor modulator. Nalmefene is an antagonist of MOR and DOR, and a partial agonist of KOR. Nalmefene has anti-inflammatory and neuroprotective activities. Nalmefene can be used in the research of reducing alcohol-dependent disorders .

HY-A0118A

Naloxegol oxalate 2 Publications Verification NKTR-118 oxalate; AZ-13337019 oxalate	Opioid Receptor	Metabolic Disease
Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 oxalate) is an orally active peripherally acting *μ-opioid* receptor** antagonist with a target K_i of 7.42 nM. Naloxegol oxalate inhibits the binding of opioids to μ-opioid receptors in the gastrointestinal tract, and alleviates opioid-induced gastrointestinal hypomotility, delayed transit, hypertonicity, and increased fluid reabsorption. Naloxegol oxalate is applicable to research related to opioid-induced constipation .

HY-13243

Alvimopan 2 Publications Verification ADL 8-2698; LY 246736	Opioid Receptor	Neurological Disease
Alvimopan (ADL 8-2698) is a potent, selective, orally active and reversible *μ-opioid* receptor** antagonist, with an IC₅₀ of 1.7 nM. Alvimopan has selectivity for μ-opioid receptor (K_i=0.47 nM) over κ- and *δ-opioid* receptors (K_i**s=100, 12 nM, respectively). Alvimopan can be used for the research of postoperative ileus .

HY-10487

JDTic dihydrochloride 3 Publications Verification	Opioid Receptor	Neurological Disease
JDTic (dihydrochloride) is a potent antagonist of *kappa-opioid* receptors (KOR)*, blocking the κ-agonist* U50, 488-induced antinociception.

HY-13274

JTC-801 5+ Cited Publications	Opioid Receptor	Neurological Disease
JTC-801 is a selective opioid receptor-like1 (ORL1) receptor antagonist, binding to ORL1 receptor with a K_i value of 8.2 nM.

HY-100903

Norbinaltorphimine dihydrochloride 5+ Cited Publications nor-Binaltorphimine dihydrochloride; nor-BNI dihydrochloride	Opioid Receptor	Neurological Disease
Norbinaltorphimine dihydrochloride (nor-Binaltorphimine dihydrochloride; nor-BNI dihydrochloride) is a selective, long-acting competitive antagonist of the *κ-opioid* receptor*. Norbinaltorphimine dihydrochloride blocks κ-opioid* receptor-mediated analgesic effects, and inhibits butorphanol-induced changes in κ-opioid receptor binding kinetics, desensitization and down-regulation. Norbinaltorphimine dihydrochloride suppresses specific opioid withdrawal symptoms, precipitates withdrawal behaviors in butorphanol-dependent rats, and serves as a molecular probe for studying κ-opioid receptor-agonist interactions. Norbinaltorphimine dihydrochloride is applicable to research related to neurological disorders such as pain .

HY-117040

nor-Binaltorphimine 5+ Cited Publications Norbinaltorphimine; NorBNI	Opioid Receptor	Neurological Disease
nor-Binaltorphimine (Norbinaltorphimine; NorBNI) is a selective, long-acting competitive antagonist of the *κ-opioid* receptor*. nor-Binaltorphimine blocks κ-opioid* receptor-mediated analgesic effects, and inhibits butorphanol-induced changes in κ-opioid receptor binding kinetics, desensitization and down-regulation. nor-Binaltorphimine suppresses specific opioid withdrawal symptoms, precipitates withdrawal behaviors in butorphanol-dependent rats, and serves as a molecular probe for studying κ-opioid receptor-agonist interactions. nor-Binaltorphimine is applicable to research related to neurological disorders such as pain .

HY-101302

Naltriben mesylate 2 Publications Verification	Opioid Receptor TRP Channel	Inflammation/Immunology
Naltriben mesylate is a potent *δ2-opioid* receptor** antagonist and a TRPM7 activator. Naltriben mesylate shows K_i values of 0.013 nM, 19 nM and 152 nM for δ, μ and κ receptors, respectively. Naltriben mesylate enhances glioblastoma cell migration and invasion. Naltriben mesylate can be used in research into neurological diseases and cancer .

HY-123689

Samidorphan ALKS-33; RDC-0313	Opioid Receptor	Neurological Disease
Samidorphan (ALKS-33) is an orally active *opioid* system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan primarily acts as an opioid receptor antagonist in vivo. Samidorphan can improve the behavior of depressed animals .

HY-101376

(+)-N-Allylnormetazocine hydrochloride (+)-SKF 10047 hydrochloride; (+)-N-Allyl-N-normetazocine hydrochloride	Opioid Receptor	Neurological Disease
(+)-N-Allylnormetazocine ((+)-SKF 10047) hydrochloride is a benzomorphan opioid with psychotomi metic effects. (+)-N-Allylnormetazocine hydrochloride is an opioid receptor antagonist with K_i values of 300 nM and 27 μM for σ1 and σ2 opioid receptors, respectively. (+)-N-Allylnormetazocine hydrochloride can be used for the research of neurological disease .

HY-107749

ML 190	Opioid Receptor	Neurological Disease
ML 190 is a selective *κ opioid* receptor (KOR)** antagonist with an IC₅₀ of 120 nM and an EC₅₀ of 129 nM, respectively .

HY-101011

Naloxonazine dihydrochloride	Opioid Receptor	Infection Neurological Disease
Naloxonazine dihydrochloride is a specific *μ-opioid* receptor** antagonist with an IC₅₀ of 5.4 nM. Naloxonazine dihydrochloride also shows anti-leishmanial activity .

HY-107748

5'-Guanidinonaltrindole hydrochloride 5'-GNTI hydrochloride	Opioid Receptor	Neurological Disease
5'-Guanidinonaltrindole (5'-GNTI) hydrochloride is a highly selective and potent *κ-opioid* receptor** antagonist with a K_i of 0.18 nM for human κ-opioid receptor .

HY-100122

Bevenopran 1 Publications Verification CB-5945; ADL-5945	Opioid Receptor	Neurological Disease
Bevenopran is a peripheral *μ-opioid* receptor** antagonist .

HY-108229

6β-Naltrexol 6β-Hydroxynaltrexone	Drug Metabolite Opioid Receptor	Neurological Disease
6β-Naltrexol (6β-Hydroxynaltrexone), the primary metabolite of Naltrexone, is a peripherally selective *opioid* antagonist. 6β-Naltrexol selectively inhibits gastrointestinal opioid effects in human subjects and inhibits Morphine-induced slowing of gastrointestinal transit .

HY-19627

Naldemedine S-297995	Opioid Receptor	Neurological Disease Metabolic Disease
Naldemedine (S-297995) is an orally active *μ-opioid* receptor** antagonist (PAMORA) . Naldemedine shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC₅₀=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors . Naldemedine can be used in opioid-induced constipation (OIC) research . Naldemedine is predicted to bind to 3CL ^pro encoded by SARS-CoV2 genome .

HY-137279

Naloxone methiodide 1 Publications Verification	Opioid Receptor	Inflammation/Immunology
Naloxone methiodide is a peripherally restricted, nonselective, and competitive opioid receptor antagonist. Naloxone methiodide does not penetrate the blood-brain barrier .

HY-136208

TAN-452	Opioid Receptor	Neurological Disease
TAN-452 is an orally active, selective peripherally acting *δ-opioid* receptor (DOR)** antagonist with a K_i of 0.47 nM and a K_b of 0.21 nM. TAN-452 is an antagonist for *μ-opioid* receptor (MOR; K_i=36.56 nM and K_b=9.43 nM) and κ-opioid receptor (KOR; K_i=5.31 nM and K_b**=7.18 nM). TAN-452, a derivative of Naltrindole, demonstrates low brain penetrability and attenuates morphine-induced side effects without affecting pain control .

HY-W013154

Fmoc-Tic-OH	Amino Acid Derivatives	Others
Fmoc-Tic-OH is an amino acid derivative with an Fmoc protecting group, which can be used to synthesize bioactive peptide mimetics, such as the biotinylated derivative of the opioid receptor antagonist TIPP .

HY-D1387

Naloxone fluorescein acetate	Fluorescent Dye	Neurological Disease
Naloxone fluorescein acetate is the fluorescent-derivative of Naloxone. Naloxone is an opioid antagonist. Naloxone is the antidote for reversing the effects of an opioid overdose .

HY-76711R

Naltrexone (Standard)	Reference Standards Opioid Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Naltrexone (Standard) is the analytical standard of Naltrexone (HY-76711). This product is intended for research and analytical applications. Naltrexone is an orally active, long-acting opioid receptor (opioid receptor) antagonist. Naltrexone blocks the euphoric effects of exogenous opioids and reduces alcohol craving by blocking opioid receptors (μ, κ, and δ) as well as opioid growth factor receptors. Low doses of Naltrexone are used to relieve chronic pain, treat inflammatory diseases and inhibit tumor growth, while high doses or continuous administration exert pro-inflammatory or pro-proliferative effects. Naltrexone relieves intractable pruritus caused by psoriasis, atopic dermatitis and other conditions, and its combination with Bupropion (HY-B0403) inhibits food craving, thereby reducing body weight.

HY-174422

Opioid receptor antagonist 2	Opioid Receptor	Others
Opioid receptor antagonist 2 (Compound 9) is a potent opioid receptor antagonist. Opioid receptor antagonist 2 can reverse ventilatory depression and vocal cord closure induced by fentanyl analogs in mice. Opioid receptor antagonist 2 is promising for research of acute poisoning such as respiratory depression caused by overdose of opioids .

HY-101307

BNTX maleate 7-Benzylidenenaltrexone maleate	Opioid Receptor	Neurological Disease
BNTX (7-Benzylidenenaltrexone) maleate is a *δ1-opioid* receptor antagonist with the K_is of 0.1, 10.8, 13.3, and 58.6 nM for δ1, δ2-, μ-, and κ-opioid receptor, respectively. BNTX maleate shows antinociceptive activity .

HY-17417R

Naloxone hydrochloride (Standard)	Reference Standards Opioid Receptor	Neurological Disease Cancer
Naloxone (hydrochloride) (Standard) is the analytical standard of Naloxone (hydrochloride). This product is intended for research and analytical applications. Naloxone hydrochloride is an antagonist of Opioid receptor. Naloxone hydrochloride alleviates opioid-overdose-induced respiratory depression. Naloxone hydrochloride may cause pulmonary edema and cardiac arrhythmias .

HY-107750A

Cyprodime hydrochloride	Opioid Receptor	Neurological Disease
Cyprodime hydrochloride is a highly selective *μ-opioid* receptor** antagonist with K_i values of 5.4 nM, 244.6 nM and 2187 nM for μ-, δ- and κ-opioid receptors, respectively. Cyprodime hydrochloride has anti-depressant-like effect .

HY-76657A

Alvimopan dihydrate 2 Publications Verification ADL 8-2698 dihydrate; LY 246736 dihydrate	Opioid Receptor	Neurological Disease Cancer
Alvimopan dihydrate (ADL 8-2698 dihydrate) is a potent, selective, orally active and reversible *μ-opioid* receptor** antagonist, with an IC₅₀ of 1.7 nM. Alvimopan dihydrate has selectivity for μ-opioid receptor (K_i=0.47 nM) over κ- and *δ-opioid* receptors (K_i**s=100, 12 nM, respectively). Alvimopan dihydrate can be used for the research of postoperative ileus .

HY-16979

TRK-851	Opioid Receptor	Neurological Disease
RK-851 is a highly selective and orally active *δ-opioid* receptor** antagonist, with a negative logarithm of the antagonist concentration (pA₂) of 8.84. TRK-851 exhibits the selectivity for the δ receptor of more than 100 times higher than that for the μ or κ receptors. TRK-851 exhibits a potent antitussive effect in a rat model of capsaicin-induced cough. TRK-851 can be used for research on antitussive effects .

HY-107121

Ondelopran LY 2196044	Opioid Receptor	Neurological Disease
Ondelopran (LY 2196044) is a non-selective opioid receptor antagonist. Ondelopran inhibits the release of dopamine in the nucleus accumbens induced by alcohol, reduces the rewarding effect of alcohol consumption, and lowers the craving. Ondelopran can be used for alcohol use disorder (AUD) .

HY-144609

*Mu opioid* receptor antagonist 4**	Opioid Receptor	Neurological Disease
Mu opioid receptor antagonist 4 (compound 31) is a potent and selective *μ opioid* receptor (MOR)** antagonist with a K_i of 0.38 nM and an EC₅₀ of 1.07 nM. Mu opioid receptor antagonist 4 has remarkable CNS antagonism against morphine, and precipitated fewer withdrawal symptoms than Naloxone. Mu opioid receptor antagonist 4 Mu opioid receptor antagonist 4 can be used for researching opioid use disorders (OUD) .

HY-107743

Naloxone benzoylhydrazone NalBzoH	Opioid Receptor	Neurological Disease
Naloxone benzoylhydrazone (NalBzoH) is a mixed agonist/antagonist. Naloxone benzoylhydrazone is a prototypic *κ3-opioid* receptor** agonist, and a partial agonist at the cloned μ and *δ opioid* receptors*, and an antagonist* at opioid-like NOP receptors. Naloxone benzoylhydrazone has potently analgesia effect .

HY-155320

*Mu opioid* receptor antagonist 7**	Opioid Receptor	Neurological Disease
Mu opioid receptor antagonist 7 (compound 24) is a potent and CNS permeable antagonist of *µOR (µ-opioid* receptor), with an IC₅₀** of 29 ± 3.0 nM. Mu opioid receptor antagonist 7 can be used for the research of pain and opioid use disorder .

HY-10486

JDTic	Opioid Receptor	Neurological Disease
JDTic is a highly selective antagonist for the κ-opioid receptor; without affecting the μ- or δ-opioid receptors.

HY-144607

*Mu opioid* receptor antagonist 2**	Opioid Receptor	Neurological Disease
Mu opioid receptor antagonist 2 (compound 25) is a potent, selective and blood-brain barrier (BBB) penetrant *μ opioid* receptor (MOR)** antagonist with a K_i of 0.37 nM and an EC₅₀ of 0.44 nM. Mu opioid receptor antagonist 2 has remarkable CNS antagonism against morphine, and precipitated fewer withdrawal symptoms than Naloxone. Mu opioid receptor antagonist 2 can be used for researching opioid use disorders (OUD) .

HY-144606

*Mu opioid* receptor antagonist 1**	Opioid Receptor	Neurological Disease
Mu opioid receptor antagonist 1 (compound 19) is a selective and orally active *μ opioid* receptor (MOR) ligand with an K_i value of 0.58 nM and an EC₅₀** of 1.15 nM. Orally administrating with Mu opioid receptor antagonist 1 increases intestinal motility during morphine-induced constipation. Mu opioid receptor antagonist 1 can be used for researching opioid-induced constipation (OIC) .

HY-156614

Icalcaprant	Opioid Receptor	Neurological Disease
Icalcaprant is a kappa-opioid receptor antagonist .

HY-101233

ICI 154129 M 154129	Opioid Receptor	Neurological Disease
ICI 154 129 is a *delta-opioid* receptor** antagonist and can be used for seizure research.

HY-169867

BNTX 7-Benzylidenenaltrexone	Opioid Receptor	Neurological Disease
BNTX (7-Benzylidenenaltrexone) is a highly selective *δ1 opioid* receptor** antagonist. BNTX selectively antagonizes the antinociceptive activity mediated by spinal δ₁ opioid receptors, and does not alter the antinociceptive effects mediated by δ₂, μ or κ opioid receptors at selective doses .

HY-114072A

(S,S)-J-113397	Opioid Receptor	Neurological Disease
(S,S)-J-113397 is an isomer of J-113397 (HY-114072). J-113397 is an Opioid Receptor antagonist .

HY-178235

MDAN-21	Opioid Receptor	Neurological Disease
MDAN-21 is a bivalent opioid ligand that contains both *μ-opioid* receptor** agonists and *δ-opioid* receptor** antagonists. MDAN-21 has a strong analgesic effect and does not produce tolerance in mouse studies. MDAN-21 can effectively inhibit the withdrawal of morphine dependent monkeys and alleviate abnormal pain in the study of rhesus monkeys. MDAN-21 can be used for the study of allodynia .

HY-19902

GSK1521498	Opioid Receptor	Neurological Disease
GSK1521498 is a potent and selective *μ-opioid* receptor (MOR)** antagonist. GSK1521498 has the potential for disorders of compulsive consumption of food, alcohol, and agents .

HY-N12180A

Hodgkinsine	Opioid Receptor Bacterial Fungal	Infection Neurological Disease
Hodgkinsine is an *opioid* receptor agonist and NMDA receptor antagonist, which has analgesic and anti-injurial effects. In addition, Hodgkinsine has antiviral, antibacterial and antifungal activities .

HY-B1485

Nalmefene hydrochloride	Opioid Receptor	Neurological Disease
Nalmefene hydrochloride is a long acting opioid (MOR and DOR antagonist), and a partial KOR agonist. Nalmefene hydrochloride is used for opioid overdose and alcohol dependence .

HY-163895

*δ opioid* receptor antagonist 1**	Fluorescent Dye Opioid Receptor	Neurological Disease
δ opioid receptor antagonist 1 (compound 6-Cy3) is a fluorescent antagonist probe with high selectivity for δ opioid receptor (DOR) (K_i=1.7 nM). δ opioid receptor antagonist 1 can be used to study the mechanism of pain perception .

HY-175661

SRI-22136	Opioid Receptor Beta-secretase	Neurological Disease
SRI-22136 is a Delta Opioid Receptor (DOR) antagonist that can cross blood-brain barrier with a IC₅₀ of 0.42 nM. SRI-22136 does not have agonistic activity but antagonistic activity against DOR, MOR (IC₅₀ = 370 nM), KOR (IC₅₀ = 54 nM) and can avoid addiction/aversion effects. SRI-22136 can effectively inhibit the BACE1 activity induced by DADLE (a DOR agonist) (HY-105343) (IC₅₀ = 120 nM). SRI-22136 prevents completely Alzheimer’s-like pathology in mouse model. SRI-22136 can used for the study of Alzheimer’s disease .

HY-170654

Opioid receptor antagonist 1	Opioid Receptor	Neurological Disease
Opioid receptor antagonist 1 (Compound 10) is an Orvinol (HY-D0168)-based opioid receptor antagonist. Opioid receptor antagonist 1 has antagonistic activity to the analgesic properties of Morphine .

Cat. No.	Product Name	Target	Research Area

HY-P1852

TIP 39, Tuberoinfundibular Neuropeptide 1 Publications Verification	Adenylate Cyclase PTHR	Neurological Disease
TIP 39, Tuberoinfundibular Neuropeptide is an endogenous PTH2 receptor agonist and antihypertensive agent. TIP 39, Tuberoinfundibular Neuropeptide selectively activates the PTH2 receptor with no activity on the PTH1 receptor, stimulates cAMP production, activates adenylate cyclase, and elevates intracellular calcium levels via mobilization from intracellular stores. TIP 39, Tuberoinfundibular Neuropeptide is highly conserved in humans, mice, and rats. TIP 39, Tuberoinfundibular Neuropeptide is applicable to research related to nociception and inflammation-induced pain .

HY-P1335

CTAP 2 Publications Verification	Opioid Receptor	Neurological Disease
CTAP is a potent, highly selective, and BBB penetrant *μ opioid* receptor** antagonist, with an IC₅₀ of 3.5 nM. CTAP displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and somatostatin receptors. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

HY-W013154

Fmoc-Tic-OH	Amino Acid Derivatives	Others
Fmoc-Tic-OH is an amino acid derivative with an Fmoc protecting group, which can be used to synthesize bioactive peptide mimetics, such as the biotinylated derivative of the opioid receptor antagonist TIPP .

HY-P1335A

CTAP TFA 2 Publications Verification	Opioid Receptor	Neurological Disease
CTAP TFA is a potent, highly selective, and BBB penetrant *μ opioid* receptor** antagonist, with an IC₅₀ of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and somatostatin receptors. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

HY-P1329A

CTOP TFA 1 Publications Verification	Opioid Receptor	Neurological Disease
CTOP TFA is a potent and highly selective *μ-opioid* receptor** antagonist. CTOP TFA antagonizes the acute analgesic effect and hypermotility. CTOP TFA enhances extracellular dopamine levels in the nucleus accumbens. CTOP TFA dose-dependently enhances locomotor activity .

HY-101230

ICI 174864	Opioid Receptor	Neurological Disease
ICI 174864 is a selective and brain-penetrant *δ-opioid* receptor** antagonist with K_e values of 22.0 nM to 30.6 nM at δ-opioid receptor in mouse vas deferens. ICI 174864 selectively blocks biological effects mediated by the δ-opioid receptor agonist DPDPE (HY-P1334) after central administration. ICI 174864 reverses hypotension in rats with endotoxic shock and inhibits acetic acid-induced writhing in mice. ICI 174864 can be used for the research of opioid receptor subtypes, endotoxic hypotension and analgesic pathways .

HY-P1329

CTOP	Opioid Receptor	Neurological Disease
CTOP is a potent and highly selective *μ-opioid* receptor** antagonist. CTOP antagonizes the acute morphine-induced analgesic effect and hypermotility. CTOP enhances extracellular dopamine levels in the nucleus accumbens. CTOP dose-dependently enhances locomotor activity .

HY-P1299A

UFP-101 TFA	Opioid Receptor	Neurological Disease
UFP-101 TFA is a potent, selective, and competitive antagonist of the N/OFQ peptide (NOP) receptor, with a pK_i of 10.24. UFP-101 TFA displays >3000-fold selectivity over δ, μ and κ opioid receptors. UFP-101 TFA shows antidepressant-like effect .

HY-P10395

DP50	Opioid Receptor Neuropeptide FF Receptor	Neurological Disease
DP50 is a bifunctional compound that contains an opioid receptor (MOP) agonist and a neuropeptide FF receptor (NPFFR) antagonist. DP50 can be used in analgesia-related research .

HY-P10394

DP32	Opioid Receptor Neuropeptide FF Receptor	Neurological Disease
DP32 is a bifunctional compound that contains an opioid receptor (MOP) agonist and a neuropeptide FF receptor (NPFFR) antagonist. DP32 can be used in analgesia-related research .

HY-P1299

UFP-101	Opioid Receptor	Neurological Disease
UFP-101 is a potent, selective, and competitive antagonist of the NOP receptor, with a pK_i of 10.24. UFP-101 displays >3000-fold selectivity over δ, μ and κ opioid receptors. UFP-101 shows antidepressant-like effect .

HY-P3839

Nocistatin	Opioid Receptor	Neurological Disease
Nocistatin, a neuropeptide, is an endogenous ligand for the *orphan opioid* receptor-like receptor*. Nocistatin is also a functional antagonist* of neuropeptide nociceptin or orphanin FQ (Noc/OFQ). Nocistatin inhibits 5-HT release via a G_i/o proteinmediated pathway. Nocistatin blocks Nociceptin (Nociceptin)-induced allodynia and hyperalgesia .

HY-P2669

Boc-YPGFL(O-tBu)	Opioid Receptor	Neurological Disease
Boc-YPGFL(O-tBu) is a selective *δ opioid* receptor (DOR)** peptide antagonist .

HY-129422

Diallyl G	Opioid Receptor	Neurological Disease
Diallyl G is a *delta-opioid* receptor** antagonist. Diallyl G shows inhibitory effect on GTPase .

HY-P10177

Acetalin-3	Opioid Receptor	Neurological Disease
Acetalin-3 (Ac-RFMWMT-NH2), a hexapeptide, is a *μ opioid* receptor** antagonist with high affinity for μ and κ3 opioid receptor, weak affinity for κ1 receptors and no affinity for κ2 receptors .

HY-P10175

Acetalin-1	Opioid Receptor	Neurological Disease
Acetalin-1 (Ac-RFMWMK-NH2), a hexapeptide, is a *μ opioid* receptor** antagonist with high affinity for μ and κ3 opioid receptor, weak affinity for κ1 receptors and no affinity for κ2 receptors .

HY-P2052

AWL 60	Opioid Receptor Neurokinin Receptor	Others
AWL 60 is a compound with SP antagonist and weak opioid agonist properties, which can antagonize SP-agonists in vitro and attenuate the decrease in blood pressure caused by SP-agonists in vivo.

HY-P5892

β-Endorphin (1-27) (human)	Opioid Receptor	Neurological Disease
β-Endorphin (1-27) (human) is an *opioid* antagonist that binds μ-, δ-, and κ-opioid receptors with K_is of 5.31, 6.17, and 39.82 nM, respectively. β-Endorphin (1-27) (human) inhibits β-Endorphin (HY-P1502)-induced and etorphine-induced analgesia .

HY-P2429

N,N-Diallyl-Tyr-Aib-Aib-Phe-Leu	Opioid Receptor	Others
N,N-Diallyl-Tyr-Aib-Aib-Phe-Leu is a compound that can antagonize the δ-opioid receptor and the action of [D-Pen2,D-Pen ] enkephalin in vivo. Its antagonistic effect can be verified by specific behavioral experiments.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0193

Prazosin 15+ Cited Publications	Classification of Application Fields Disease Research Fields Endocrinology	Adrenergic Receptor
Prazosin is an α-adrenergic receptor antagonist. Prazosin can reduce inflammation, relieve anxiety, alleviate panic, prevent memory decline, and modulate the pain-relieving effects of opioids. Prazosin can be used in the study of hypertension and Alzheimer’s disease .

HY-B0188A

Mianserin hydrochloride 1 Publications Verification Org GB 94	Alkaloids Structural Classification Neurological Disease Classification of Application Fields Leguminosae Other Alkaloids Crotalaria pallida Ait. Plants Disease Research Fields Endocrinology Source Classification	Histamine Receptor Opioid Receptor ERK p38 MAPK
Mianserin hydrochloride (Org GB 94) is an orally active H1 receptor antagonist. Mianserin hydrochloride can activate *κ-opioid* receptor and octopamine receptor. Mianserin hydrochloride increases ERK1/2 and CREB** phosphorylation, and antagonizes full κ-opioid agonist and Dynorphin A (HY-P1333)-induced MAPK phosphorylation. Mianserin hydrochloride modulates social and exploratory behaviour, raises electroconvulsive thresholds. Mianserin hydrochloride can be used for the research of neurological disease, such as depression and epilepsy .

HY-N12180A

Hodgkinsine	Alkaloids Arecaceae Bercht. & J. Presl Rubiaceae Arecaceae Plants Indole Alkaloids Source Classification	Opioid Receptor Bacterial Fungal
Hodgkinsine is an *opioid* receptor agonist and NMDA receptor antagonist, which has analgesic and anti-injurial effects. In addition, Hodgkinsine has antiviral, antibacterial and antifungal activities .

HY-A0115R

Ramiprilat (Standard) HOE 498 diacid (Standard); Ramipril diacid (Standard)	Structural Classification Alkaloids Pyrrole Alkaloids Endogenous metabolite Source Classification	Drug Metabolite Reference Standards Angiotensin-converting Enzyme (ACE) Endogenous Metabolite
Alvimopan (dihydrate) (Standard) is the analytical standard of Alvimopan (dihydrate). This product is intended for research and analytical applications. Alvimopan dihydrate (ADL 8-2698 dihydrate) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC50 of 1.7 nM. Alvimopan dihydrate has selectivity for μ-opioid receptor (Ki=0.47 nM) over κ- and δ-opioid receptors (Kis=100, 12 nM, respectively). Alvimopan dihydrate can be used for the research of postoperative ileus .

HY-B0188AR

Mianserin hydrochloride (Standard) Org GB 94 (Standard)	Alkaloids Structural Classification Leguminosae Other Alkaloids Crotalaria pallida Ait. Plants Source Classification	Reference Standards Histamine Receptor Opioid Receptor ERK p38 MAPK
Mianserin hydrochloride (Org GB 94) (Standard) is the analytical standard of Mianserin hydrochloride. This product is intended for research and analytical applications. Mianserin hydrochloride is an orally active H1 receptor antagonist. Mianserin hydrochloride can activate *κ-opioid* receptor and octopamine receptor. Mianserin hydrochloride increases ERK1/2 and CREB** phosphorylation, and antagonizes full κ-opioid agonist and Dynorphin A (HY-P1333)-induced MAPK phosphorylation. Mianserin hydrochloride modulates social and exploratory behaviour, raises electroconvulsive thresholds. Mianserin hydrochloride can be used for the research of neurological disease, such as depression and epilepsy .

HY-N12180

Hodgkinsine B	Alkaloids Arecaceae Bercht. & J. Presl Rubiaceae Arecaceae Plants Indole Alkaloids Source Classification	Opioid Receptor Bacterial Fungal
Hodgkinsine B is an *opioid* receptor agonist and NMDA receptor antagonist, which has analgesic and anti-injurial effects. In addition, Hodgkinsine B has antiviral, antibacterial and antifungal activities .

Cat. No.	Product Name	Chemical Structure

HY-76711S

Naltrexone-d4

Naltrexone-d4 is deuterium labeled Naltrexone (HY-76711). Naltrexone is an orally active, long-acting opioid receptor (opioid receptor) antagonist. Naltrexone blocks the euphoric effects of exogenous opioids and reduces alcohol craving by blocking opioid receptors (μ, κ, and δ) as well as opioid growth factor receptors. Low doses of Naltrexone are used to relieve chronic pain, treat inflammatory diseases and inhibit tumor growth, while high doses or continuous administration exert pro-inflammatory or pro-proliferative effects. Naltrexone relieves intractable pruritus caused by psoriasis, atopic dermatitis and other conditions, and its combination with Bupropion (HY-B0403) inhibits food craving, thereby reducing body weight.

HY-108229S

6β-Naltrexol-d3
6β-Naltrexol-d₃ (6β-Hydroxynaltrexone-d₃) is deuterium labeled 6β-Naltrexol. 6β-Naltrexol (6β-Hydroxynaltrexone), the primary metabolite of Naltrexone, is a peripherally selective *opioid* antagonist. 6β-Naltrexol selectively inhibits gastrointestinal opioid effects in human subjects and inhibits Morphine-induced slowing of gastrointestinal transit .

HY-B0188S

Mianserin-d3

Mianserin-d3 is the deuterium labeled Mianserin (HY-B0188). Mianserin (Mianserine) is an orally active H1 receptor antagonist. Mianserin can activate κ-opioid receptor and octopamine receptor. Mianserin increases ERK1/2 and CREB phosphorylation, and antagonizes full κ-opioid agonist and Dynorphin A (HY-P1333)-induced MAPK phosphorylation. Mianserin modulates social and exploratory behaviour, raises electroconvulsive thresholds. Mianserin can be used for the research of neurological disease, such as depression and epilepsy .

HY-123689S1

Samidorphan-d5

Samidorphan-d5 (ALKS-33-d5) is is a deuterated compound of Samidorphan. Samidorphan is an orally active opioid system modulator that binds with high affinity to μ-opioid, κ-opioid, and δ-opioid receptors. Samidorphan is a μ-opioid receptor antagonist and a partial agonist at k-opioid and δ-opioid receptors. Samidorphan acts primarily as an opioid receptor antagonist in vivo .

HY-17417AS

Naloxone-d5
Naloxone D5 is deuterium labeled Naloxone. Naloxone is a a potent opioid receptor antagonist.

HY-B0188AS

Mianserin-d3 hydrochloride

Mianserin-d₃ hydrochloride is the deuterium labeled Mianserin. Mianserin (Mianserine) is an orally active H1 receptor antagonist. Mianserin can activate κ-opioid receptor and octopamine receptor. Mianserin increases ERK1/2 and CREB phosphorylation, and antagonizes full κ-opioid agonist and Dynorphin A (HY-P1333)-induced MAPK phosphorylation. Mianserin modulates social and exploratory behaviour, raises electroconvulsive thresholds. Mianserin can be used for the research of neurological disease, such as depression and epilepsy .

HY-W754114

Nalmefene Sulfate-d3
Nalmefene Sulfate-d₃ is the deuterium labeled Nalmefene (HY-107744). Nalmefene is a BBB-penetrable opioid receptor modulator. Nalmefene is an antagonist of MOR and DOR, and a partial agonist of KOR. Nalmefene has anti-inflammatory and neuroprotective activities. Nalmefene can be used in the research of reducing alcohol-dependent disorders .

HY-123689S

Samidorphan-d4

Samidorphan-d4 is the deuterium labeled Samidorphan(HY-123689).Samidorphan (ALKS-33) is an orally active opioid system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan primarily acts as an opioid receptor antagonist in vivo .

HY-A0118AS

Naloxegol-d5 oxalate
Naloxegol-d₅ (oxalate) is deuterium labeled Naloxegol (oxalate). Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 oxalate) is a μ-opioid-receptor antagonist. Naloxegol oxalate inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation .

HY-A0118S

Naloxegol-13C,d3
Naloxegol- ¹³C,d₃ (NKTR-118- ¹³C,d₃) is ¹³C labeled Naloxegol. Naloxegol (NKTR-118; AZ-13337019) is a μ-opioid-receptor antagonist. Naloxegol inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation .

HY-A0118S1

Naloxegol-13C,d2
Naloxegol- ¹³C,d₂ (NKTR-118- ¹³C,d₂) is ¹³C labeled Naloxegol. Naloxegol (NKTR-118; AZ-13337019) is a μ-opioid-receptor antagonist. Naloxegol inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation .

HY-W739948

Naltrexone-d3
Naltrexone-d₃ is a deuterated labeled Naltrexone (HY-76711) . Naltrexone is an antagonist of Opioid receptor. Naltrexone inhibits cell proliferation in vivo. Naltrexone reduces tumor growth by interfering with cell signalling and modifying the immune system .

HY-106605S

Flumezapine-d8 hydrochloride

Flumezapine-d₈ (LY 120363-d₈) hydrochloride is deuterated labeled Flumezapine hydrochloride. Flumezapine hydrochloride is a potent and balanced antagonist of the dopamine D2 receptor and the 5-hydroxytryptamine receptor (5-HT receptor). Flumezapine hydrochloride does not alter the increase in serum cortisol caused by κ-opioid receptor agonists. Flumezapine hydrochloride inhibits the conditioned avoidance response in rats and has a low risk of extrapyramidal side effects. Flumezapine hydrochloride can be used in antipsychotic research.

HY-13243S1

Alvimopan-d7

Alvimopan-d₇ (ADL 8-2698-d₇) is deuterium labeled Alvimopan. Alvimopan (ADL 8-2698) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC₅₀ of 1.7 nM. Alvimopan has selectivity for μ-opioid receptor (K_i=0.47 nM) over κ- and δ-opioid receptors (K_is=100, 12 nM, respectively). Alvimopan can be used for the research of postoperative ileus .

HY-W709349S

Flupirtine-d6 hydrochloride

Flupirtine-d₆ (D 9998-d₆) hydrochloride is the deuterium labeled Flupirtine hydrochloride (HY-W709349). Flupirtine hydrochloride is an orally active, blood-brain barrier-crossing non-opioid analgesic and neuroprotective agent. Flupirtine hydrochloride is a neuronal potassium channel opener (Kv7 activator), a NMDA receptor antagonist and a GABA receptor activator. Flupirtine hydrochloride stabilizes blood-brain-barrier integrity, reduces oxidative stress and brain leukocyte infiltration, enhances angioneurogenesis, suppresses calcium influx, stabilizes neuronal resting membrane potential, and counteracts focal cerebral ischemia. Flupirtine hydrochloride exhibits analgesic, muscle relaxant properties, protects neurons from excitotoxic, ischemic, or cytokine-mediated death. Flupirtine hydrochloride functions as a non-opioid analgesic without antipyretic or antiphlogistic properties, shows no relevant affinity to opiate receptor. Flupirtine hydrochloride can be used for the research of focal cerebral ischemia, pain, Alzheimer’s disease, or multiple sclerosis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks